We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Spending growth for prescription drugs in the U.S. decelerated at a rapid rate
in 2003, according to new data released by the Centers for Medicare & Medicaid
Services (CMS).
Wyeth has agreed to support an amendment to a nationwide
legal settlement with users of its fen-phen products -- a move that would guarantee
payments to the largest group of members involved in the class action lawsuit.
Several prominent Democrats have sent a letter to the Government Accountability Office (GAO) asking the watchdog agency to examine "covert propaganda" being employed by the Bush administration, including actions related to the Medicare Modernization Act (MMA).
It would be a mistake to remove the FDA's drug safety office from the agency
as a way to ensure total independence from the new drug office, says an industry
expert who cautioned the FDA and lawmakers not to overreact to recent adverse
events surrounding Cox-2 inhibitors.
An Australian biotech company has acquired Myomatrix
Therapeutics of Rensselaer, N.Y. Terms of the deal were not disclosed. Cytopia
Inc., a wholly owned subsidiary of Cytopia Ltd., plans to add staff once the
merger is completed. Shreefal Mehta, Myomatrix CEO, will be vice president of
the merged entity.
Shire Pharmaceuticals remains committed to protecting the patents which it has
relating to Adderall XR, its product for treatment of attention-deficit/hyperactivity
disorder (ADHD).
Pharmacy benefits manager Caremark on Monday said all the products it sells
come from licensed wholesalers, a day after a published report said Illinois
regulators were investigating whether it resold drugs that had been returned
by patients.
Oxygen Healthcare, promoted by a group of UK-based NRIs, is setting up a world-class
research facility in Ahmedabad to offer contract chemistry in drug discovery
for bio-pharmaceutical companies based in Europe and the U.S.
A pharmaceutical company has issued a nationwide recall of approximately 500
bottles of a drug used to treat attention-deficit/hyperactivity disorder and
narcolepsy.
Women's rights groups seeking easier access to emergency contraception are pressuring
U.S. regulators as they try to decide whether to approve a nonprescription "morning-after"
pill.